irinotecan has been researched along with adenosine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kaneko, S; Mizuno, K; Okada, M | 1 |
| Borst, P; Greenberger, L; Jonkers, J; Rottenberg, S; Sol, W; van Tellingen, O; Zander, SA; Zhang, Y | 1 |
| Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W | 1 |
1 review(s) available for irinotecan and adenosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for irinotecan and adenosine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum.
Topics: Adenosine; Animals; Antihypertensive Agents; Caffeine; Camptothecin; Dopamine; Enzyme Inhibitors; Extracellular Space; Irinotecan; Male; Microdialysis; Neostriatum; Phenethylamines; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P1; Theobromine; Vasodilator Agents | 1996 |
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; BRCA1 Protein; Camptothecin; Diketopiperazines; DNA Topoisomerases, Type I; Female; Gene Expression; Heterocyclic Compounds, 4 or More Rings; Irinotecan; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Mutation; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2012 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GPI-Linked Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, Purinergic P1; Survival Rate | 2019 |